| Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis M Lemstra, D Blackburn, A Crawley, R Fung Canadian journal of cardiology 28 (5), 574-580, 2012 | 225 | 2012 |
| Tapering opioids using motivational interviewing A Crawley, L Murphy, L Regier, N McKee Canadian Family Physician 64 (8), 584-587, 2018 | 18 | 2018 |
| Navigating cannabinoid choices for chronic neuropathic pain in older adults: potholes and highlights R Kamrul, D Bunka, A Crawley, B Schuster, M LeBras Canadian Family Physician 65 (11), 807-811, 2019 | 11 | 2019 |
| Pharmacotherapy management of schizophrenia for family physicians J Bool, A Crawley, A Wanson, B Davis, K Halpape Canadian Family Physician 67 (5), 350-354, 2021 | 6 | 2021 |
| Evaluation of a medication safety and adherence program within a First Nations community in Saskatchewan, Canada R Erker, Q Alefan, D Goodridge, A Crawley, N Rabbitskin, S Bighead, ... Journal of the American Pharmacists Association 61 (1), e39-e45, 2021 | 3 | 2021 |
| Thoughtful prescribing for patients with difficult-to-treat depression A Soubolsky, J Visentin, A Crawley Canadian Family Physician 69 (11), 777, 2023 | 2 | 2023 |
| Do prior authorization policies discourage first-line antipsychotic use in patients newly discharged from a hospitalization for schizophrenia in Saskatchewan? DF Blackburn, D Tran, A Crawley, S Lynds, A Champagne, L Bresee, ... Journal of Population Therapeutics and Clinical Pharmacology= Journal de la …, 2014 | 2 | 2014 |
| Prescription réfléchie pour les patients souffrant d’une dépression difficile à traiter A Soubolsky, J Visentin, A Crawley Canadian Family Physician 69 (11), e221, 2023 | 1 | 2023 |
| Prise en charge pharmacothérapeutique de la schizophrénie à l’intention des médecins de famille J Bool, A Crawley, A Wanson, B Davis, K Halpape Canadian Family Physician 67 (5), e115-e120, 2021 | 1 | 2021 |
| An Advanced Pharmacy Practice Experience for Community Pharmacies Based on a Clinical Intervention Targeting Patients With Inflammatory Bowel Disease DF Blackburn, S Fowler, A Crawley, S Gerwing, J Alcorn, H Mansell, ... Journal of Pharmacy Practice 34 (1), 51-57, 2021 | 1 | 2021 |
| Pharmacologic management of COPD: Breadth of products for encouraging a breath of air A Crawley, T Laubscher, P Muddiman, L Kosar Canadian Family Physician 62 (5), 410-414, 2016 | 1 | 2016 |
| Perles cliniques sur la prise en charge des migraines A Crawley, J Myers, LD Regier Canadian Family Physician 70 (5), e66-e69, 2024 | | 2024 |
| Clinical pearls for management of migraines A Crawley, J Myers, LD Regier Canadian Family Physician 70 (5), 325-327, 2024 | | 2024 |
| RE: Resistance Does Not Exist AJ Crawley | | 2024 |
| Nirmatrelvir-ritonavir for outpatients with COVID-19. Case-based approach to assessment and treatment M LeBras, A Crawley, M Legge, S Takaya, S Lee, L Regier CANADIAN FAMILY PHYSICIAN 69 (8), E170-E174, 2023 | | 2023 |
| Le nirmatrelvir-ritonavir pour les patients non hospitalisés atteints de la COVID-19: Approche de l’évaluation et du traitement, fondée sur des cas M LeBras, A Crawley, M Legge, S Takaya, S Lee, L Regier Canadian Family Physician 69 (8), e170, 2023 | | 2023 |
| Nirmatrelvir-ritonavir for nonhospitalized patients with COVID-19: Case-based approach to assessment and treatment M LeBras, A Crawley, M Legge, S Takaya, S Lee, L Regier Canadian Family Physician 69 (8), 546, 2023 | | 2023 |
| Inappropriate administration: The silent culprit in drug therapy problems J Vitic, E Yakiwchuk, A Crawley CANADIAN FAMILY PHYSICIAN 69 (2), E38-E44, 2023 | | 2023 |
| Improper administration: Silent culprit of drug therapy problems J Vitic, E Yakiwchuk, A Crawley Canadian Family Physician 69 (2), 107-112, 2023 | | 2023 |
| Une administration inappropriée: La silencieuse coupable de problèmes en pharmacothérapie J Vitic, E Yakiwchuk, A Crawley Canadian Family Physician 69 (2), e38-e44, 2023 | | 2023 |
